Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years
Status:
Completed
Trial end date:
2019-01-11
Target enrollment:
Participant gender:
Summary
Positive results in preclinical and clinical studies in adults and infants with Prader-Willi
syndrome lead investigators to set up a new study in children with Prader-Willi syndrome. The
objective of this study is to document effects of oxytocin intranasal administrations on
behavioural troubles in children with Prader-Willi syndrome aged from 3 to 12 years.